B-intervention	0	11	Ixabepilone
I-intervention	12	16	plus
I-intervention	17	29	capecitabine
O	30	32	in
O	33	43	metastatic
O	44	50	breast
O	51	57	cancer
O	58	66	patients
O	67	71	with
O	72	79	reduced
O	80	91	performance
O	92	98	status
O	99	109	previously
O	110	117	treated
O	118	122	with
O	123	137	anthracyclines
O	138	141	and
O	142	149	taxanes
O	149	150	:
O	151	152	a
O	153	159	pooled
O	160	168	analysis
O	169	171	by
O	172	183	performance
O	184	190	status
O	191	193	of
O	194	202	efficacy
O	203	206	and
O	207	213	safety
O	214	218	data
O	219	223	from
O	224	225	2
O	226	231	phase
O	232	235	III
O	236	243	studies
O	243	244	.

O	245	253	Patients
O	254	258	with
O	259	269	metastatic
O	270	276	breast
O	277	283	cancer
O	284	285	(
O	285	288	MBC
O	288	289	)
O	290	300	previously
O	301	308	treated
O	309	313	with
O	314	328	anthracyclines
O	329	332	and
O	333	340	taxanes
O	341	346	often
O	347	351	have
O	352	361	decreased
O	362	373	performance
O	374	380	status
O	381	390	secondary
O	391	393	to
O	394	403	extensive
O	404	409	tumor
O	410	421	involvement
O	421	422	.

O	423	427	Here
O	427	428	,
O	429	431	we
O	432	438	report
O	439	442	the
O	443	449	pooled
O	450	458	analysis
O	459	461	of
O	462	470	efficacy
O	471	474	and
O	475	481	safety
O	482	486	data
O	487	491	from
O	492	495	two
O	496	505	similarly
O	506	514	designed
O	515	520	phase
O	521	524	III
O	525	532	studies
O	533	535	to
O	536	543	provide
O	544	545	a
O	546	550	more
O	551	558	precise
O	559	567	estimate
O	568	570	of
O	571	578	benefit
O	579	581	of
O	582	593	ixabepilone
O	594	598	plus
O	599	611	capecitabine
O	612	614	in
O	615	618	MBC
O	619	627	patients
O	628	632	with
O	633	642	Karnofsky
O	642	643	'
O	643	644	s
O	645	656	performance
O	657	663	status
O	664	665	(
O	665	668	KPS
O	668	669	)
O	670	672	70
O	672	673	-
O	673	675	80
O	675	676	.

O	677	683	Across
O	684	687	the
O	688	695	studies
O	695	696	,
B-eligibility	697	710	anthracycline
I-eligibility	710	711	/
I-eligibility	711	717	taxane
I-eligibility	717	718	-
I-eligibility	718	728	pretreated
I-eligibility	729	732	MBC
I-eligibility	733	741	patients
O	742	746	were
O	747	757	randomized
O	758	760	to
O	761	768	receive
O	769	780	ixabepilone
O	781	785	plus
O	786	798	capecitabine
O	799	801	or
B-control	802	814	capecitabine
I-control	815	820	alone
O	820	821	.

O	822	832	Individual
O	833	840	patient
O	841	845	data
O	846	849	for
O	850	853	KPS
O	854	856	70
O	856	857	-
O	857	859	80
O	860	866	subset
O	867	868	(
O	868	869	n
O	870	871	=
B-total-participants	872	875	606
O	875	876	)
O	877	879	or
O	880	883	KPS
O	884	886	90
O	886	887	-
O	887	890	100
O	891	897	subset
O	898	899	(
O	899	900	n
O	901	902	=
B-total-participants	903	907	1349
O	907	908	)
O	909	913	from
O	914	917	the
O	918	921	two
O	922	929	studies
O	930	934	were
O	935	941	pooled
O	942	944	by
O	945	954	treatment
O	954	955	.

O	956	964	Analysis
O	965	973	included
O	974	981	overall
O	982	990	survival
O	991	992	(
O	992	994	OS
O	994	995	)
O	995	996	,
O	997	1008	progression
O	1008	1009	-
O	1009	1013	free
O	1014	1022	survival
O	1023	1024	(
O	1024	1027	PFS
O	1027	1028	)
O	1028	1029	,
O	1030	1039	objective
O	1040	1048	response
O	1049	1053	rate
O	1054	1055	(
O	1055	1058	ORR
O	1058	1059	)
O	1059	1060	,
O	1061	1064	and
O	1065	1071	safety
O	1071	1072	.

O	1073	1075	In
O	1076	1084	patients
O	1085	1089	with
O	1090	1097	reduced
O	1098	1109	performance
O	1110	1116	status
O	1117	1118	(
O	1118	1121	KPS
O	1122	1124	70
O	1124	1125	-
O	1125	1127	80
O	1127	1128	)
O	1128	1129	,
O	1130	1141	ixabepilone
O	1142	1146	plus
O	1147	1159	capecitabine
O	1160	1163	was
O	1164	1174	associated
O	1175	1179	with
O	1180	1192	improvements
O	1193	1195	in
B-outcome	1196	1198	OS
O	1199	1200	(
O	1200	1206	median
O	1206	1207	:
B-iv-cont-median	1208	1210	12
I-iv-cont-median	1210	1211	.
I-iv-cont-median	1211	1212	3
O	1213	1215	vs
O	1215	1216	.
B-cv-cont-mean	1217	1218	9
I-cv-cont-mean	1218	1219	.
I-cv-cont-mean	1219	1220	5
I-cv-cont-mean	1221	1227	months
O	1227	1228	;
O	1229	1231	HR
O	1231	1232	,
O	1233	1234	0
O	1234	1235	.
O	1235	1237	75
O	1237	1238	;
O	1239	1240	P
O	1241	1242	=
O	1243	1244	0
O	1244	1245	.
O	1245	1249	0015
O	1249	1250	)
O	1250	1251	,
B-outcome	1252	1255	PFS
O	1256	1257	(
O	1257	1263	median
O	1263	1264	:
B-iv-cont-median	1265	1266	4
I-iv-cont-median	1266	1267	.
I-iv-cont-median	1267	1268	6
O	1269	1271	vs
O	1271	1272	.
B-cv-cont-median	1273	1274	3
I-cv-cont-median	1274	1275	.
I-cv-cont-median	1275	1276	1
I-cv-cont-median	1277	1283	months
O	1283	1284	;
O	1285	1287	HR
O	1287	1288	,
O	1289	1290	0
O	1290	1291	.
O	1291	1293	76
O	1293	1294	;
O	1295	1296	P
O	1297	1298	=
O	1299	1300	0
O	1300	1301	.
O	1301	1305	0021
O	1305	1306	)
O	1307	1310	and
B-outcome	1311	1314	ORR
O	1315	1316	(
B-iv-bin-percent	1316	1318	35
O	1319	1321	vs
O	1321	1322	.
B-cv-bin-percent	1323	1325	19
I-cv-bin-percent	1325	1326	%
O	1326	1327	)
O	1328	1332	over
O	1333	1345	capecitabine
O	1346	1351	alone
O	1351	1352	.

O	1353	1366	Corresponding
O	1367	1374	results
O	1375	1377	in
O	1378	1386	patients
O	1387	1391	with
O	1392	1396	high
O	1397	1408	performance
O	1409	1415	status
O	1416	1417	(
O	1417	1420	KPS
O	1421	1423	90
O	1423	1424	-
O	1424	1427	100
O	1427	1428	)
O	1429	1433	were
B-outcome	1434	1440	median
I-outcome	1441	1443	OS
O	1444	1446	of
B-iv-cont-median	1447	1449	16
I-iv-cont-median	1449	1450	.
I-iv-cont-median	1450	1451	7
O	1452	1458	versus
B-cv-cont-median	1459	1461	16
I-cv-cont-median	1461	1462	.
I-cv-cont-median	1462	1463	2
I-cv-cont-median	1464	1470	months
O	1471	1472	(
O	1472	1474	HR
O	1474	1475	,
O	1476	1477	0
O	1477	1478	.
O	1478	1480	98
O	1480	1481	;
O	1482	1483	P
O	1484	1485	=
O	1486	1487	0
O	1487	1488	.
O	1488	1492	8111
O	1492	1493	)
O	1493	1494	,
B-outcome	1495	1501	median
I-outcome	1502	1505	PFS
O	1506	1508	of
B-iv-cont-median	1509	1510	6
I-iv-cont-median	1510	1511	.
I-iv-cont-median	1511	1512	0
O	1513	1519	versus
B-cv-cont-median	1520	1521	4
I-cv-cont-median	1521	1522	.
I-cv-cont-median	1522	1523	4
I-cv-cont-median	1524	1530	months
O	1531	1532	(
O	1532	1534	HR
O	1534	1535	,
O	1536	1537	0
O	1537	1538	.
O	1538	1540	58
O	1540	1541	;
O	1542	1543	P
O	1544	1545	=
O	1546	1547	0
O	1547	1548	.
O	1548	1552	0009
O	1552	1553	)
O	1553	1554	,
O	1555	1558	and
B-outcome	1559	1562	ORR
O	1563	1565	of
B-iv-bin-percent	1566	1568	45
O	1569	1575	versus
B-cv-bin-percent	1576	1578	28
I-cv-bin-percent	1578	1579	%
O	1579	1580	.

O	1581	1584	The
B-outcome	1585	1591	safety
I-outcome	1592	1599	profile
O	1600	1602	of
O	1603	1614	combination
O	1615	1622	therapy
O	1623	1626	was
O	1627	1634	similar
O	1635	1642	between
O	1643	1646	the
O	1647	1656	subgroups
O	1656	1657	.

O	1658	1669	Ixabepilone
O	1670	1674	plus
O	1675	1687	capecitabine
O	1688	1696	appeared
O	1697	1699	to
O	1700	1704	show
O	1705	1713	superior
O	1714	1722	efficacy
O	1723	1731	compared
O	1732	1734	to
O	1735	1747	capecitabine
O	1748	1753	alone
O	1754	1756	in
O	1757	1760	MBC
O	1761	1769	patients
O	1770	1780	previously
O	1781	1788	treated
O	1789	1793	with
O	1794	1808	anthracyclines
O	1809	1812	and
O	1813	1820	taxanes
O	1820	1821	,
O	1822	1832	regardless
O	1833	1835	of
O	1836	1847	performance
O	1848	1854	status
O	1854	1855	,
O	1856	1860	with
O	1861	1862	a
O	1863	1871	possible
O	1872	1874	OS
O	1875	1882	benefit
O	1883	1891	favoring
O	1892	1895	KPS
O	1896	1898	70
O	1898	1899	-
O	1899	1901	80
O	1902	1910	patients
O	1911	1912	(
O	1912	1926	ClinicalTrials
O	1926	1927	.
O	1928	1931	gov
O	1932	1943	identifiers
O	1943	1944	:
O	1945	1956	NCT00080301
O	1957	1960	and
O	1961	1972	NCT00082433
O	1972	1973	)
O	1973	1974	.
